OTLK (Outlook Therapeutics) FFO


OTLK Outlook Therapeutics Inc OTLK
11 GF Score
Price $1.73
! 6 Warning Signs
View Full Analysis

What is Outlook Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

OTLK
11GF Score
Outlook Therapeutics Inc OTLK
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Outlook Therapeutics Business Description

Other Exchanges 41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
11GF Score

Get the complete analysis for OTLK

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.73
Price